In our investigation of the underlying mechanisms, we made an intriguing discovery: the expression levels of SP100 family members were significantly higher in PAAD tissues with TP53 mutations compared to those with wild-type TP53. The gene discussed is SP100; the disease is pancreatic adenocarcinoma.